Meeting
2016 ASCO Annual Meeting
Costs associated with adverse events for systemic therapies in metastatic melanoma.
Authors
Ying Qiu
Novartis Pharmaceuticals Corporation, East Hanover, NJ
Ying Qiu , Zhiyi Li , Jackson Tang , Kris Grzegorzewski , Syed Mahmood , Tyler Whisman , Syed Quadri , Alex Z Fu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9560)
DOI
10.1200/JCO.2016.34.15_suppl.9560
Abstract #
9560
Poster Bd #
165
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series.
First Author: Umang Swami
Poster
2016 ASCO Annual Meeting
Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor-infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma.
First Author: MarnixMarnix Heimen Geukes Foppen
Poster
2013 ASCO Annual Meeting
NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).
First Author: Douglas Buckner Johnson
Poster
2019 ASCO Annual Meeting
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
First Author: Nikhil I. Khushalani